PragmatIC Semiconductor Secures $80 Million Funding
19 Oct, 2021
– Caribou Biosciences, Inc. announced the successful completion of an oversubscribed $115m Series C financing.
– Proceeds from the financing will be used to further develop the Company’s proprietary, next-generation CRISPR technology platform and to advance the Company’s pipeline of wholly-owned allogeneic immune cell therapies for oncology with best-in-class potential.
– The Series C financing was co-led by new premier healthcare investors Farallon Capital Management, PFM Health Sciences, and Ridgeback Capital Investments.